Publications by authors named "Rick Vreman"

Claim this Profile
E
Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis.
Milou A Hogervorst, Rick A Vreman, Theresa A Oduol, Aukje K Mantel-Teeuwisse, Wim G Goettsch

Clin Pharmacol Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability.
Marcelien H E Callenbach, Rick A Vreman, Christine Leopold, Aukje K Mantel-Teeuwisse, Wim G Goettsch

Pharmacoeconomics· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stimulating development of innovative medicines in the European Union: does a new definition for unmet medical need add value?
Lourens T Bloem, Hubert G M Leufkens, Sophie E Berends, Rick A Vreman, Carla E M Hollak

Drug Discov Today· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncertainty in Long-Term Relative Effectiveness of Medicines in Health Technology Assessment.
Jan-Willem Versteeg, Rick Vreman, Aukje Mantel-Teeuwisse, Wim Goettsch

Value Health· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®).
Marcelien H E Callenbach, Daphne Schoenmakers, Rick A Vreman, Sylvia Vijgen, Lonneke Timmers

Value Health· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations.
Jorge Madrid Paredes, Jan-Willem Versteeg, Rick A Vreman, Lourens T Bloem

Clin Pharmacol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lifecycle HTA: promising applications and a framework for implementation. An HTAi Global Policy Forum Task Force report.
Franz B Pichler, Meindert Boysen, Nicole Mittmann, Ramiro Gilardino, Andrew Bruce, Rick A Vreman

Int J Technol Assess Health Care· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An operationalization framework for lifecycle health technology assessment: a Health Technology Assessment International Global Policy Forum Task Force report.
Franz B Pichler, Meindert Boysen, Nicole Mittmann, Ramiro Gilardino, Andrew Bruce, Rick A Vreman

Int J Technol Assess Health Care· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A literature review of quality assessment and applicability to HTA of risk prediction models of coronary heart disease in patients with diabetes.
Li Jiu, Junfeng Wang, Francisco Javier Somolinos-Simón, Jose Tapia-Galisteo, Gema García-Sáez, Rick A Vreman

Diabetes Res Clin Pract· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries.
Zoltán Kaló, Maciej Niewada, Tamás Bereczky, Wim Goettsch, Rick A Vreman

Expert Rev Pharmacoecon Outcomes Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tools for assessing quality of studies investigating health interventions using real-world data: a literature review and content analysis.
Li Jiu, Michiel Hartog, Junfeng Wang, Rick A Vreman, Olaf H Klungel

BMJ Open· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group - author's reply.
Milou Amber Hogervorst, Rick Vreman, Inkatuuli Heikkinen, Wija Oortwijn

Int J Technol Assess Health Care· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic anticancer treatment in the Netherlands: Few hospitals treat many patients, many hospitals treat few patients.
Niels W L Peeters, Rick A Vreman, Geert A Cirkel, Marie José Kersten, Hanneke W M van Laarhoven

Health Policy· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts.
Milou A Hogervorst, Mathias Møllebæk, Rick A Vreman, Ting-An Lu, Junfeng Wang

BMJ Open· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries' past health technology assessments.
Rick A Vreman, Daan van Hoof, Anna Nachtnebel, Joël Daems, Marc van de Casteele

Int J Technol Assess Health Care· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group.
Milou Amber Hogervorst, Rick Vreman, Inkatuuli Heikkinen, Indranil Bagchi, Inaki Gutierrez-Ibarluzea

Int J Technol Assess Health Care· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergy between health technology assessments and clinical guidelines for multiple sclerosis.
Milou A Hogervorst, Rick A Vreman, Anna Zawada, Magdalena Zielińska, Dalia M Dawoud

Clin Transl Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.
Comfort K Ogar, Jonathan Quick, Hannah N Gilbert, Rick A Vreman, Aukje K Mantel-Teeuwisse

Drug Saf· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook.
Marcelien H E Callenbach, Lldikó Ádám, Rick A Vreman, Bertalan Németh, Zoltán Kaló

Drug Discov Today· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome.
Wout W A van den Broek, Jacqueline G van Paassen, Marieke E Gimbel, Vera H M Deneer, Jurriën M Ten Berg, Rick A Vreman

Eur Heart J Cardiovasc Pharmacother· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs.
Marcelien H E Callenbach, Rick A Vreman, Aukje K Mantel-Teeuwisse, Wim G Goettsch

Int J Environ Res Public Health· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome-based reimbursement in Central-Eastern Europe and Middle-East.
Ildikó Ádám, Marcelien Callenbach, Bertalan Németh, Rick A Vreman, Cecilia Tollin

Front Med (Lausanne)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delayed payment schemes in Central-Eastern Europe and Middle-East.
Ildikó Ádám, Marcelien Callenbach, Bertalan Németh, Rick A Vreman, Johan Pontén

Front Med (Lausanne)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.
Joost J Enzing, Saskia Knies, Jop Engel, Maarten J IJzerman, Beate Sander, Rick Vreman

Cost Eff Resour Alloc· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory reliance pathways during health emergencies: enabling timely authorizations for COVID-19 vaccines in Latin America.
Ivar T van der Zee, Rick A Vreman, Lawrence Liberti, Mario Alanis Garza

Rev Panam Salud Publica· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis